7Baggers
 ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know  sharewise.com Tue, 18 Nov 2025 21:11:32 GMT
 Wall Street Zen Upgrades ADC Therapeutics (NYSE:ADCT) to "Hold"  MarketBeat Sun, 16 Nov 2025 07:20:02 GMT
 FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald  MarketBeat Fri, 14 Nov 2025 15:58:34 GMT
 Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC  Fierce Biotech Thu, 13 Nov 2025 15:15:00 GMT
 ADC Therapeutics S.A. (NYSE:ADCT) Q3 2025 Earnings Call Transcript  Insider Monkey Tue, 11 Nov 2025 13:37:25 GMT
 adc therapeutics sa (adct) reports q3 loss, tops revenue estimates  sharewise.com Tue, 11 Nov 2025 07:43:13 GMT
 ADC Therapeutics Reports Q3 2025 Financial Results  TipRanks Tue, 11 Nov 2025 04:14:58 GMT
 ADC Therapeutics Q3 2025 Earnings Call Highlights  TipRanks Tue, 11 Nov 2025 00:13:54 GMT
 ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)  TipRanks Mon, 10 Nov 2025 19:29:49 GMT
 adc therapeutics q3 2025 earnings call transcript  MarketBeat Mon, 10 Nov 2025 15:22:30 GMT
 ADC Therapeutics (ADCT) Earnings Call Transcript  The Motley Fool Mon, 10 Nov 2025 14:17:00 GMT
 ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance Mon, 10 Nov 2025 13:40:02 GMT
 adc therapeutics : 3q 2025 earnings presentation  MarketScreener Mon, 10 Nov 2025 13:36:09 GMT
 adc therapeutics sa (adct) q3 fy2025 earnings call transcript  Yahoo Finance Mon, 10 Nov 2025 13:30:00 GMT
 ADC Therapeutics Q3 net income beats analyst expectations  TradingView Mon, 10 Nov 2025 12:42:50 GMT
 earnings scheduled for november 10, 2025  Benzinga Mon, 10 Nov 2025 11:12:02 GMT
 fy2025 eps forecast for adc therapeutics boosted by analyst  MarketBeat Sat, 08 Nov 2025 14:22:57 GMT
 whitehawk therapeutics, inc. sec 10-q report  TradingView Thu, 06 Nov 2025 18:53:00 GMT
 adc therapeutics sa hits new 52-week high of $4.80  Markets Mojo Sun, 02 Nov 2025 09:56:34 GMT

ADC Therapeutics
(NYSE:ADCT) 

ADCT stock logo

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical tria...

Founded: 2011
CEO: Christopher John Martin  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends